Advertisement

Clinical Rheumatology

, Volume 35, Issue 4, pp 857–861 | Cite as

Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study

  • A. Gardette
  • S. Ottaviani
  • J. Sellam
  • F. Berenbaum
  • F. Lioté
  • A. Meyer
  • J. Sibilia
  • B. Fautrel
  • E. Palazzo
  • P. DieudéEmail author
Original Article

Abstract

Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA). Little is known about the impact of body mass index (BMI) on other biologic agents. We aimed to evaluate the effect of BMI on response to tocilizumab (TCZ) in RA. RA patients treated with TCZ were included in this multicenter retrospective study. BMI was calculated at the initiation of treatment. After 6 months of treatment, change from baseline in DAS28, pain on a visual analog scale, erythrocyte sedimentation rate and C-reactive protein level, and tender and swollen joints were analyzed. The primary endpoint was decrease in DAS28 ≥ 1.2. Secondary outcomes were good response and remission by EULAR criteria. At baseline, among 115 RA patients included, the median (interquartile range) BMI was 25.4 (22.0–28.8) kg/m2. The number of patients with normal weight, overweight, and obesity was 53 (46 %), 37 (32 %), and 25 (22 %), respectively. Baseline characteristics did not differ between the three subgroups of BMI. The median BMI did not differ between responders and non-responders for DAS28 decrease ≥1.2 (25.7 [22.1–29.9] vs 24.9 [22.0–27.1], P = 0.38), EULAR good response (25.9 [22.8–30.0] vs 25.4 [22.0–28.4], P = 0.61), and remission (25.1 [22.5–28.6] vs 25.4 [22.0–28.9], P = 0.76). BMI did not affect the response to TCZ in RA. If confirmed, these results could be helpful for the selection of a biologic agent in obese RA patients.

Keywords

Obesity Rheumatoid arthritis Tocilizumab 

Notes

Acknowledgments

We thank Laura Smales for copyediting.

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    WHO (2000) Obesity: preventing and managing the global epidemic. Tech Rep Ser 894Google Scholar
  2. 2.
    Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772–783CrossRefPubMedGoogle Scholar
  3. 3.
    Muller-Ladner U, Neumann E (2009) Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 5(12):659–660CrossRefPubMedGoogle Scholar
  4. 4.
    Stavropoulos-Kalinoglou A, Metsios G, Koutedakis Y, Kitas G (2011) Obesity in rheumatoid arthritis. Rheumatology (Oxford) 50(3):450–462CrossRefGoogle Scholar
  5. 5.
    Naranjo A, Sokka T, Descalzo M, Calvo-Alén J, Hørslev-Petersen K, Luukkainen R, Combe B, Burmester G, Devlin J, Ferraccioli G et al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Armstrong D, McCausland E, Quinn A, Wright G (2006) Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 45:782CrossRefGoogle Scholar
  7. 7.
    Voigt L, Koepsell T, Nelson J, Dugowson C, Daling J (1994) Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 5:525–532PubMedGoogle Scholar
  8. 8.
    Symmons D, Bankhead C, Harrison B, Brennan P, Barrett E, Scott D, Silman A (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40:1955–1961CrossRefPubMedGoogle Scholar
  9. 9.
    Ajeganova S, Andersson M, Hafström I, Group BS (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow up from disease onset. Arthritis Care Res 65(1):78–87CrossRefGoogle Scholar
  10. 10.
    Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 56(11):3575–3582CrossRefPubMedGoogle Scholar
  11. 11.
    van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67(6):769–774CrossRefPubMedGoogle Scholar
  12. 12.
    Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G (2003) Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 30(11):2350–2355PubMedGoogle Scholar
  13. 13.
    Mirpourian M, Salesi M, Abdolahi H, Farajzadegan Z, Karimzadeh H (2014) The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci 19(6):509–514PubMedPubMedCentralGoogle Scholar
  14. 14.
    Sandberg ME, Bengtsson C, Kallberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S (2014) Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 73(11):2029–2033CrossRefPubMedGoogle Scholar
  15. 15.
    Klaasen R, Wijbrandts C, Gerlag D, Tak P (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359–364CrossRefPubMedGoogle Scholar
  16. 16.
    Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina A et al (2013) Obesity and reduction of the response rate to anti-tumour necrosis factor alphain rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 65(1):94–100CrossRefGoogle Scholar
  17. 17.
    Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF (2013) Association of high body mass index with decreased treatment response to combination therapy in recent onset rheumatoid arthritis patients. Arthritis Care Res 65:1235–1242CrossRefGoogle Scholar
  18. 18.
    Minno MD, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, Minno GD (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 65:141–147CrossRefGoogle Scholar
  19. 19.
    Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman D (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813–817CrossRefPubMedGoogle Scholar
  20. 20.
    Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A, Pasquet B et al (2012) Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 14(3):R115CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli M, Zoli A et al (2014) Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford) 53(5):875–881CrossRefGoogle Scholar
  22. 22.
    Pers YM, Godfrin-Valnet M, Lambert J, Fortuet C, Constant E, Mura T, Pallot-Prades B, Jorgensen C, Maillefert JF, Marotte H et al (2015) Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 42(4):580–584CrossRefPubMedGoogle Scholar
  23. 23.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMedGoogle Scholar
  24. 24.
    Smolen J, Landewé R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Furst D, Keystone E, So A, Braun J, Breedveld F, Burmester G, De Benedetti F, Dörner T, Emery P, Fleischmann R et al (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72(Suppl2):ii2–ii34PubMedGoogle Scholar
  26. 26.
    van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845–1850CrossRefPubMedGoogle Scholar
  27. 27.
    de Rooy D, van der Linden M, Knevel R, Huizinga T, Van der Helm-van Mil A (2011) Predicting arthritis outcomes—what can be learned from the Leiden early arthritis clinic? Rheumatology (Oxford) 50(1):93–100CrossRefGoogle Scholar
  28. 28.
    Neumann E, Frommer K, Vasile M, Muller-Ladner U (2011) Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 63(5):1159–1169CrossRefPubMedGoogle Scholar
  29. 29.
    Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87CrossRefPubMedGoogle Scholar
  30. 30.
    Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, Zhang Y (2013) The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One 8(10), e78151CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Stavropoulos-Kalinoglou A, Metsios G, Panoulas V, Nightingale P, Koutedakis Y, Kitas G (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitvity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14(4):R160CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86(3):1154–1159CrossRefPubMedGoogle Scholar
  34. 34.
    Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M (2010) Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 5(12), e14328CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2016

Authors and Affiliations

  • A. Gardette
    • 1
  • S. Ottaviani
    • 1
  • J. Sellam
    • 2
  • F. Berenbaum
    • 2
  • F. Lioté
    • 3
  • A. Meyer
    • 4
    • 5
  • J. Sibilia
    • 4
  • B. Fautrel
    • 6
  • E. Palazzo
    • 1
  • P. Dieudé
    • 1
    • 7
    Email author
  1. 1.CHU Bichat Claude Bernard, Service de RhumatologieUniversité Paris Diderot, Hôpital Bichat, AP-HPParisFrance
  2. 2.CHU Saint Antoine, Service de Rhumatologie, DHU i2B and Inserm UMRS_938Université Pierre et Marie CurieParisFrance
  3. 3.Inserm, UMR-S 606, CHU Lariboisière, Service de RhumatologieUniversité Paris DiderotParisFrance
  4. 4.Service de RhumatologieHôpitaux Universitaires de StrasbourgStrasbourgFrance
  5. 5.Service de physiologie exploration fonctionnelle musculaireHôpitaux Universitaires de StrasbourgStrasbourgFrance
  6. 6.CHU La Pitié Salpétrière, Service de RhumatologieUniversité Pierre et Marie CurieParisFrance
  7. 7.Inserm, U1149, CNRS-ERL8252Université Paris DiderotParisFrance

Personalised recommendations